S&P 500   4,586.77 (+0.77%)
DOW   35,666.66 (+0.50%)
QQQ   383.46 (+0.91%)
AAPL   152.60 (+2.52%)
MSFT   323.44 (+0.08%)
FB   316.23 (+1.28%)
GOOGL   2,914.30 (-0.34%)
TSLA   1,068.01 (+2.91%)
AMZN   3,469.11 (+2.26%)
NVDA   248.04 (+1.44%)
BABA   169.77 (+0.32%)
NIO   40.41 (+2.80%)
CGC   13.02 (+1.88%)
GE   104.51 (+0.64%)
AMD   120.97 (-1.07%)
MU   69.45 (+1.77%)
T   25.62 (+2.23%)
F   16.82 (+8.45%)
ACB   6.92 (+1.17%)
DIS   170.23 (+0.40%)
PFE   43.17 (+0.47%)
BA   208.08 (+0.71%)
AMC   34.98 (+0.63%)
S&P 500   4,586.77 (+0.77%)
DOW   35,666.66 (+0.50%)
QQQ   383.46 (+0.91%)
AAPL   152.60 (+2.52%)
MSFT   323.44 (+0.08%)
FB   316.23 (+1.28%)
GOOGL   2,914.30 (-0.34%)
TSLA   1,068.01 (+2.91%)
AMZN   3,469.11 (+2.26%)
NVDA   248.04 (+1.44%)
BABA   169.77 (+0.32%)
NIO   40.41 (+2.80%)
CGC   13.02 (+1.88%)
GE   104.51 (+0.64%)
AMD   120.97 (-1.07%)
MU   69.45 (+1.77%)
T   25.62 (+2.23%)
F   16.82 (+8.45%)
ACB   6.92 (+1.17%)
DIS   170.23 (+0.40%)
PFE   43.17 (+0.47%)
BA   208.08 (+0.71%)
AMC   34.98 (+0.63%)
S&P 500   4,586.77 (+0.77%)
DOW   35,666.66 (+0.50%)
QQQ   383.46 (+0.91%)
AAPL   152.60 (+2.52%)
MSFT   323.44 (+0.08%)
FB   316.23 (+1.28%)
GOOGL   2,914.30 (-0.34%)
TSLA   1,068.01 (+2.91%)
AMZN   3,469.11 (+2.26%)
NVDA   248.04 (+1.44%)
BABA   169.77 (+0.32%)
NIO   40.41 (+2.80%)
CGC   13.02 (+1.88%)
GE   104.51 (+0.64%)
AMD   120.97 (-1.07%)
MU   69.45 (+1.77%)
T   25.62 (+2.23%)
F   16.82 (+8.45%)
ACB   6.92 (+1.17%)
DIS   170.23 (+0.40%)
PFE   43.17 (+0.47%)
BA   208.08 (+0.71%)
AMC   34.98 (+0.63%)
S&P 500   4,586.77 (+0.77%)
DOW   35,666.66 (+0.50%)
QQQ   383.46 (+0.91%)
AAPL   152.60 (+2.52%)
MSFT   323.44 (+0.08%)
FB   316.23 (+1.28%)
GOOGL   2,914.30 (-0.34%)
TSLA   1,068.01 (+2.91%)
AMZN   3,469.11 (+2.26%)
NVDA   248.04 (+1.44%)
BABA   169.77 (+0.32%)
NIO   40.41 (+2.80%)
CGC   13.02 (+1.88%)
GE   104.51 (+0.64%)
AMD   120.97 (-1.07%)
MU   69.45 (+1.77%)
T   25.62 (+2.23%)
F   16.82 (+8.45%)
ACB   6.92 (+1.17%)
DIS   170.23 (+0.40%)
PFE   43.17 (+0.47%)
BA   208.08 (+0.71%)
AMC   34.98 (+0.63%)
NASDAQ:IMTX

Immatics Stock Forecast, Price & News

$13.41
-0.04 (-0.30 %)
(As of 10/28/2021 01:41 PM ET)
Add
Compare
Today's Range
$13.41
$13.60
50-Day Range
$11.58
$15.46
52-Week Range
$9.58
$18.42
Volume
1,314 shs
Average Volume
327,508 shs
Market Capitalization
$843.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive IMTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.


Immatics logo

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tübingen, Germany.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMTX
Employees
285
Year Founded
N/A

Sales & Book Value

Annual Sales
$35.70 million
Book Value
($2.27) per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$843.61 million
Next Earnings Date
12/1/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

889th out of 1,372 stocks

Biological Products, Except Diagnostic Industry

137th out of 197 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Immatics (NASDAQ:IMTX) Frequently Asked Questions

Is Immatics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Immatics stock.
View analyst ratings for Immatics
or view top-rated stocks.

What stocks does MarketBeat like better than Immatics?

Wall Street analysts have given Immatics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Immatics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Immatics?

Immatics saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 2,940,000 shares, an increase of 20.0% from the September 30th total of 2,450,000 shares. Based on an average trading volume of 127,300 shares, the short-interest ratio is presently 23.1 days. Approximately 7.0% of the shares of the stock are short sold.
View Immatics' Short Interest
.

When is Immatics' next earnings date?

Immatics is scheduled to release its next quarterly earnings announcement on Wednesday, December 1st 2021.
View our earnings forecast for Immatics
.

How were Immatics' earnings last quarter?

Immatics (NASDAQ:IMTX) released its earnings results on Tuesday, August, 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.08. The firm earned $6.25 million during the quarter, compared to the consensus estimate of $10.15 million.
View Immatics' earnings history
.

What price target have analysts set for IMTX?

3 brokerages have issued 1-year price targets for Immatics' shares. Their forecasts range from $13.00 to $27.00. On average, they anticipate Immatics' share price to reach $20.00 in the next year. This suggests a possible upside of 49.1% from the stock's current price.
View analysts' price targets for Immatics
or view top-rated stocks among Wall Street analysts.

Who are Immatics' key executives?

Immatics' management team includes the following people:
  • Dr. Harpreet Singh, CEO, MD & Member of Management Board (Age 47)
  • Dr. Hans-George Rammensee, Co-Founder & Member of the Scientific Advisory Board
  • Dr. Toni Weinschenk Ph.D., Co-Founder & Chief Innovation Officer (Age 48)
  • Mr. Arnd Christ, Chief Financial Officer (Age 55)
  • Ms. Jessica Mosby Ed.D., Sr. Director HR & Operations
  • Mr. Steffen Walter Ph.D., Chief Technology Officer (Age 45)
  • Mr. Edward A. Sturchio, Gen. Counsel
  • Ms. Anja Heuer B.Sc., Sr. Mang. of Corp. Communications
  • Dr. Carsten Reinhardt, Chief Devel. Officer (Age 54)
  • Dr. Rainer Kramer, Chief Bus. Officer (Age 57)

What other stocks do shareholders of Immatics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), CorMedix (CRMD), Datadog (DDOG), Forte Biosciences (FBRX), (GAU), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX).

What is Immatics' stock symbol?

Immatics trades on the NASDAQ under the ticker symbol "IMTX."

Who are Immatics' major shareholders?

Immatics' stock is owned by many different institutional and retail investors. Top institutional investors include Belvedere Trading LLC (0.00%).

Which major investors are buying Immatics stock?

IMTX stock was acquired by a variety of institutional investors in the last quarter, including Belvedere Trading LLC.

How do I buy shares of Immatics?

Shares of IMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immatics' stock price today?

One share of IMTX stock can currently be purchased for approximately $13.41.

How much money does Immatics make?

Immatics has a market capitalization of $843.61 million and generates $35.70 million in revenue each year. The company earns $-229.06 million in net income (profit) each year or ($1.82) on an earnings per share basis.

How many employees does Immatics have?

Immatics employs 285 workers across the globe.

What is Immatics' official website?

The official website for Immatics is www.immatics.com.

Where are Immatics' headquarters?

Immatics is headquartered at 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003.

How can I contact Immatics?

Immatics' mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The company can be reached via phone at 49-7071-539-7700.


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.